DLA
BMY.RT

Douglas Lane & Associates’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Douglas Lane & Associates’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed – – 236
2021
Q2 		$0 Buy
+10,000
New – ﹤0.01% 231
2021
Q1 		– Sell
-523,445
Closed -$361K – 223
2020
Q4 		$361K Sell
523,445
-69,416
-12% -$148K 0.01% 174
2020
Q3 		$1.33M Sell
592,861
-39,109
-6% -$112K 0.03% 130
2020
Q2 		$2.26M Sell
631,970
-65,439
-9% -$236K 0.05% 117
2020
Q1 		$2.65M Sell
697,409
-17,283
-2% -$56.9K 0.07% 113
2019
Q4 		$2.15M Buy
+714,692
New +$1.86M 0.04% 124

Douglas Lane & Associates's BMY.RT Position: Q3 2021 in Review

Douglas Lane & Associates sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q3 2021, closing a stake of 10,000 shares.

Douglas Lane & Associates first reported a position in BMY.RT in Q4 2019 and held it in 6 quarters. The position peaked at $2.65M in Q1 2020. 4 funds tracked by Wall St. Rank hold BMY.RT as of Q3 2021.

  • Douglas Lane & Associates reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q3 2021 after selling out during the quarter.
  • Douglas Lane & Associates sold 10,000 Bristol-Myers Squibb Company Contingent Value Rights shares in Q3 2021.
  • Douglas Lane & Associates first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 6 quarters.
  • Douglas Lane & Associates's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $2.65M in Q1 2020.
  • 4 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q3 2021.

Based on Douglas Lane & Associates's 13F filing for Q3 2021, filed 21 Oct 2021.